Exact sciences

Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress

Retrieved on: 
Friday, October 20, 2023
Research, Exact sciences, Multi, ESMO, Health, Biomarker, RNA, HER2, Congress, MD, Doctor of Philosophy, Paradigm, CEST, Development, ASCEND, NGS, Clinical trial, Risk, European Society for Medical Oncology, Cancer, Histology, Breast cancer, Oncology, Public, Woman, European Society of Gynaecological Oncology, FACP, Patient, Diagnosis, Exome, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Perfume

Exact Sciences is taking a robust and rigorous approach to developing an MCED test, and today unveiled its brand name, Cancerguard.

Key Points: 
  • Exact Sciences is taking a robust and rigorous approach to developing an MCED test, and today unveiled its brand name, Cancerguard.
  • Building upon decades of research, Exact Sciences is designing the Cancerguard test to harness the additive sensitivity of multiple biomarker classes to detect more early-stage cancers.
  • To learn more, visit http://www.exactsciences.com/cancerguard
    The company will host a symposium at the congress titled "Shifting the Paradigm of Cancer Detection: Multi Cancer Early Detection," featuring experts from leading oncology research institutions and Exact Sciences.
  • The European Society for Medical Oncology (ESMO) does not endorse any company, or their products/services.

Akili Announces Leadership Transition

Retrieved on: 
Friday, October 6, 2023
Entertainment, Mental Health, Health, Apps, Applications, Technology, Health Technology, Electronic Games, COVID-19, ADHD, Acquisition, Food, Frustration, Coronavirus, Organization, Culture, Attention deficit hyperactivity disorder predominantly inattentive, Friction, Deficit spending, Variable, FDA, Growth, Policy, Patient, Exact sciences, Regulation of tobacco by the U.S. Food and Drug Administration, Foundation Medicine, Life, DSM-IV codes, Quality of life, Management, Pharmaceutical industry, Dietary supplement, Yolo Akili

The leadership transition follows the company’s announcement in September that it plans to shift from a prescription to a non-prescription business model.

Key Points: 
  • The leadership transition follows the company’s announcement in September that it plans to shift from a prescription to a non-prescription business model.
  • “Akili’s transition to a non-prescription business is a springboard to transform the company and remove friction for the customers we serve.
  • Under his leadership, Akili realized the initial phase of its vision, introducing the world’s first and only clinically validated FDA-authorized video game treatment.
  • With his transition to the role of Board chair, Martucci replaced Palihapitiya who served as chair of the Board since investing in the company and facilitating its transition to a public listing in August 2022.

Clinically Trained AI Achieved High Level of Parity with Physicians in Generating Differential Diagnosis, Large-Scale Study Finds

Retrieved on: 
Wednesday, September 20, 2023
Technology, Health Technology, Health, Artificial Intelligence, Exact sciences, Hallucination, Mayo Clinic, Depression, Education, K virtual machine, Anxiety, Maccabi Healthcare Services, Elsevier, Prescription, Research, Princeton University, CNBC, App, Patient, Physician, Artificial intelligence, Test management, Diagnosis, AI, Cedars-Sinai Medical Center, Medical device, Medical imaging, Nursing, Tel Aviv University

In 57 of the most common primary care diagnoses, more than 90% agreement existed between AI-generated and clinician differential diagnoses.

Key Points: 
  • In 57 of the most common primary care diagnoses, more than 90% agreement existed between AI-generated and clinician differential diagnoses.
  • Independent clinicians adjudicators blind to the source of the diagnosis, chose K’s AI differential diagnosis as often as the clinician’s diagnosis.
  • The study also demonstrates how the AI can improve from the clinician’s feedback in a unique reinforcement learning loop.
  • The study results show AI's strong accuracy in primary care, with the possibility for AI to assist in pre-visit medical intake and differential diagnosis.

Mercy BioAnalytics Adds Marketing and Portfolio Management Leadership to Support Diagnostic Test Development and Commercialization

Retrieved on: 
Monday, September 11, 2023
Oncology, Health, Biometrics, Genetics, General Health, Biotechnology, Genomic Health, Project management office, BS, Information technology, California State University, Cancer, MBA, Jonathan Rothberg, Exact sciences, Marketing, Medtronic, Bio-Rad Laboratories, Santa Clara University, ESV, Patient, Commercial, PMO, Biopsy, Management, Chemistry, Mercy

Josh Gralapp has joined Mercy as Vice President for Marketing and Strategic Alliances, while Tim Membrino has joined as Vice President for Program and Portfolio Management.

Key Points: 
  • Josh Gralapp has joined Mercy as Vice President for Marketing and Strategic Alliances, while Tim Membrino has joined as Vice President for Program and Portfolio Management.
  • Previously, he held marketing leadership roles at Exact Sciences and Genomic Health with their urologic oncology diagnostic test portfolios.
  • His depth and breadth of experience in diagnostic test commercialization has been an immediately impactful addition to Mercy’s leadership team.
  • “I’m thrilled to join an executive team that embraces Program and Portfolio Management best practices paired with robust clinical development efforts as we drive Mercy’s test portfolio through the product realization life cycle.”

Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

Retrieved on: 
Tuesday, September 12, 2023
Oncology, Health, Genetics, Health Technology, Pharmaceutical, Biotechnology, Cancer, Multimedia, Exact sciences, Sale, Agilent Technologies, Medicine, Patient, NYSE, Medical imaging

Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences.

Key Points: 
  • Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences.
  • Financial terms of the agreement were not disclosed and are not material to either party.
  • View the full release here: https://www.businesswire.com/news/home/20230911677427/en/
    “We are pleased that Exact Sciences is acquiring Resolution Bioscience,” said Sam Raha, senior vice president, Agilent, and president, Diagnostics and Genomics Group.
  • “Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them.

Climb for a Cure Raises $1 Million to Support High-Impact Colorectal Cancer Research

Retrieved on: 
Wednesday, September 6, 2023
Survivor, Ganser, CRC, Hope, Intelligence, Cure, Human, Research, Exact sciences, Helmy Eltoukhy, Tempus, Colorectal cancer, Medicine, Merck, System, Combat, Caregiver, Disease, Tourism, Pharmaceutical industry, Natera

Springfield, Mo., Sept. 06, 2023 (GLOBE NEWSWIRE) -- In an inspiring display of unity, determination, and community support, Fight Colorectal Cancer’s Climb for a Cure event has achieved a remarkable milestone by raising $1 million to advance colorectal cancer (CRC) research.

Key Points: 
  • Springfield, Mo., Sept. 06, 2023 (GLOBE NEWSWIRE) -- In an inspiring display of unity, determination, and community support, Fight Colorectal Cancer’s Climb for a Cure event has achieved a remarkable milestone by raising $1 million to advance colorectal cancer (CRC) research.
  • Since 2016, Climb for a Cure has been embraced by colorectal cancer survivors, caregivers, and dedicated loved ones who’ve engaged in physical challenges and fundraised to support finding a cure.
  • All dollars raised by this event go toward funding high-impact colorectal cancer research.
  • The funds raised through Climb for a Cure will be channeled into groundbreaking research endeavors to drive innovation and accelerate progress in CRC research.

Harbinger Health Expands Industry-Leading Executive Team

Retrieved on: 
Wednesday, September 6, 2023
Healthcare Businesswomen's Association, Human resources, Bachelor of Science in Human Biology, Pepperdine University, Genomic Health, Computing, Natural science, University, Industry Dive, University at Buffalo, Genomics, Engineering, Biotechnology, Abbott Laboratories, Chief commercial officer, North Carolina A&T State University, Cancer, Georgia State University, Electronics, Roswell Park Comprehensive Cancer Center, CMO, CCO, Exact sciences, Marketing, Uppsala University, Business administration, Acquisition, CBO, CFO, Growth, Master of Business Administration, Foundation Medicine, SVP, Cornell University, Manufacturing engineering, Harbinger, Data science, Management, Science, Pharmacy, Hologic, Biology, Anatomy

CAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- Harbinger Health, a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced today the appointment of Dymeka Harrison as Chief Commercial Officer (CCO), Mathew Sargent as Chief Business Officer (CBO), and Gisela Paulsen as Chief Operating Officer (COO), positioning the Company for continued growth and platform and product advancement.

Key Points: 
  • "Harbinger is laser-focused on our mission to create a new cancer screening paradigm by delivering accessible and low-cost early-stage screening tools," said Dr. Hahn.
  • Gisela Paulsen joined Harbinger as Chief Operating Officer, bringing over 25 years of expertise in the life sciences industry to the team.
  • She brings experience from executive roles at leading diagnostics companies Oncocyte Corporation, Exact Sciences (legacy Genomic Health) and Genentech/Roche across functions including commercial, program management, quality and regulatory, and other administrative functions.
  • Aside from her position at Harbinger Health, Ms. Paulsen is also Vice Chair of the Healthcare Businesswomen Association where she has led nominations, strategies and digital transformation committees.

Susan G. Komen® Hosts Annual 2023 Bay Area MORE THAN PINK Walk

Retrieved on: 
Thursday, August 31, 2023
Olive, Survivor, State, Friends, Zoo, Telemundo, Breast cancer, DSI, Research, Exact sciences, THAN, Patient, San Francisco Zoo, SAN, Alpha Media, Family, Caregiver, Disease, Birth control, KNTV, Genentech

SAN FRANCISCO, Aug. 31, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, will be hosting the return of the 2023 Bay Area MORE THAN PINK Walk on Sunday, October 1, 2023, at the San Francisco Zoo & Gardens.

Key Points: 
  • SAN FRANCISCO, Aug. 31, 2023 /PRNewswire/ -- Susan G. Komen® , the world's leading breast cancer organization, will be hosting the return of the 2023 Bay Area MORE THAN PINK Walk on Sunday, October 1, 2023, at the San Francisco Zoo & Gardens.
  • "We are excited to continue to host the MORE THAN PINK Walk and welcome walkers to this event to make a difference in our fight against breast cancer," said Jenifer Weiss, State Executive Director of Northern California Susan G. Komen.
  • Breast cancer survivors and those living with metastatic disease, caregivers, family members and loved ones will come together at the annual walk.
  • Walk participants will include breast cancer survivors, metastatic breast cancer thrivers, co-survivors and supporters of Susan G. Komen.

8 Key Trends in the $106 Billion Worldwide IVD Market

Retrieved on: 
Thursday, August 31, 2023
EUA, Mayo Clinic, Immunochemistry, Test management, Coronavirus, NGS, COVID-19, 2005 in television, Danaher, Fujifilm, Ford, Research, Mass spectrometry, Biomarker, Exact sciences, Eli Lilly, Sherlock, Amazon, Siemens Healthineers, Acquisition, Polymerase chain reaction, Roche, Medicine, OTC, IVD, Growth, AI, POC, FDA, PCR, Medical device, Renewable energy, Pharmaceutical industry, Vaccine, Pfizer

ARLINGTON, Va., Aug. 31, 2023 /PRNewswire/ -- In vitro diagnostics (IVDs) remain dynamic. The IVD market is a high R&D spend industry with constant innovations and routine interest from venture capital firms in diagnostic products.  Nevertheless, the past few years have been very disruptive for IVDs. However, the resilient IVD industry has weathered the pandemic and is forging ahead with new technologies and increased opportunities that will sustain market growth through the foreseeable future.

Key Points: 
  • The IVD market is a high R&D spend industry with constant innovations and routine interest from venture capital firms in diagnostic products.
  • The global IVD test market is estimated at $106 billion in 2023 and is expected to grow 3.8% annually through 2028.
  • This conclusion is among the analysis found in The Worldwide Market for In Vitro Diagnostic Tests, 16th Edition , the brand new market research report from leading firm Kalorama Information.
  • Beyond these developments, Kalorama Information emphasizes several other key trends that will shape the present and future of IVD testing.

Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences

Retrieved on: 
Wednesday, August 30, 2023
Oncology, Health, Genetics, Health Technology, General Health, Biotechnology, DNA, Methylation, Noise, TAPS, Genomics, Enzyme, Liquid biopsy, Research, Biomarker, Exact sciences, MRD, Cytosine, Blood, Engineering, Genetic testing, Watchmaker, DNA methylation, Fine chemical, Vaccine, Antibiotics

Under the licensing agreement, Watchmaker may develop and commercialize the TAPS technology under its own brand.

Key Points: 
  • Under the licensing agreement, Watchmaker may develop and commercialize the TAPS technology under its own brand.
  • DNA methylation patterns offer dynamic and rich insights into the status of both healthy and diseased tissue.
  • In addition to the development and licensing agreement, the companies have entered into a long-term strategic supply agreement.
  • Under its terms, Watchmaker will provide Exact Sciences with access to its portfolio of best-in-class sequencing reagents and precision enzymes.